Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma.
J Cancer Res Ther
;
2006 Jan-Mar; 2(1): 20-3
Article
in English
| IMSEAR
| ID: sea-111534
ABSTRACT
BACKGROUND:
Osteogenic sarcoma (OS) is a highly malignant tumor of the bone. There are few reports in the literature regarding determination of c-erb B-2 (HER-2/neu) expression in cases of OS and also the results are quite variable.AIM:
The present study was undertaken to correlate the expression of c-erbB2 with the survival of patients of OS. SETTINGS ANDDESIGN:
A retrospective study of cases of OS, in which the expression of c-erbB-2 by immunohistochemistry (IHC) was studied and correlated with the survival rate of the patients. MATERIALS ANDMETHODS:
Out of a total of 49 cases, proper follow up data in the form of total and disease free survival was available in only 20 cases. IHC for c-erb-B2 was carried out in these 20 cases.RESULTS:
The staining pattern was as follows no staining in 3 cases, 1 + in 5 cases, 2 + in 3 cases, 3 + in 3 cases and 4 + cytoplasmic positivity in 6 cases. Statisticalanalysis:
Spearman rank correlation test was used to correlate the intensity of cytoplasmic staining of c-erbB-2 with survival rate of the patients, response to chemotherapy and metastasis.CONCLUSIONS:
Previous studies have shown that c-erbB-2/HER-2 is an independent prognostic factor in osteogenic sarcoma, but in the present study, its expression was not seen to be correlating with survival rate of the patients. Therefore, further studies are needed to reach a consensus regarding the reliability of c-erbB-2 as an independent prognostic factor in OS.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Prognosis
/
Bone Neoplasms
/
Female
/
Humans
/
Male
/
Immunohistochemistry
/
Osteosarcoma
/
Survival Analysis
/
Child
/
Predictive Value of Tests
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Language:
English
Journal:
J Cancer Res Ther
Journal subject:
Neoplasms
/
Therapeutics
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS